Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases

International Journal of Cancer

Volumn 139, Issue 3, 2016, Pages 647-656

  Løes, Inger Marie ^a,b   Immervoll, Heike ^c,d   Sorbye, Halfdan ^a,b   Angelsen, Jon Helge ^a,b   Horn, Arild ^b   Knappskog, Stian ^a,b   Lønning, Per Eystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c A lesund Hospital   (Norway)

^d Institut für Pathologie Akademisches Lehrkrankenhaus Feldkirch   (Austria)

Author keywords

chemotherapy; colorectal cancer; heterogeneity; liver metastases; mutations

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GENOMIC DNA; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53; VASCULOTROPIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER PROGNOSIS; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PROCEDURES; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOLOGICAL PARAMETERS; PIK3CA GENE; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SANGER SEQUENCING; SURVIVAL TIME; TIME TO RELAPSE; TP53 GENE; TREATMENT RESPONSE; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC HETEROGENEITY; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MUTATION; MUTATION RATE; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84963682677     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30089     Document Type: Article

References (50)

1. Grossmann I, Doornbos PM, Klaase JM, et al., Changing patterns of recurrent disease in colorectal cancer. Eur J Surg Oncol 2014; 40: 234-9.
2. Nordlinger B, Sorbye H, Glimelius B, et al., Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-15.
3. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al., Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-80.
4. Rees M, Tekkis PP, Welsh FK, et al., Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125-35.
5. Kanas GP, Taylor A, Primrose JN, et al., Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4: 283-301.
6. Fong Y, Fortner J, Sun RL, et al., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis. Of 1001 consecutive cases. Ann Surg 1999; 230: 309-18; discussion 18-21.
7. Nordlinger B, Guiguet M, Vaillant JC, et al., Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-62.
8. Gruenberger B, Scheithauer W, Punzengruber R, et al., Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008; 8: 120.
9. Brudvik KW, Kopetz SE, Li L, et al., Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 2015; 102: 1175-83.
10. Nash GM, Gimbel M, Shia J, et al., KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010; 17: 572-8.
11. Teng HW, Huang YC, Lin JK, et al., BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 2012; 106: 123-9.
12. Yaeger R, Cercek A, Chou JF, et al., BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120: 2316-24.
13. Abdalla EK, Adam R, Bilchik AJ, et al., Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13: 1271-80.
14. Kopetz S, Chang GJ, Overman MJ, et al., Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-83.
15. Diaz LA, Jr., Williams RT, Wu J, et al., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.
16. Brannon AR, Vakiani E, Sylvester BE, et al., Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014; 15: 454.
17. Mao C, Wu XY, Yang ZY, et al., Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep 2015; 5: 8065.
18. Tan IB, Malik S, Ramnarayanan K, et al., High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biol 2015; 16: 32.
19. McGranahan N, Swanton C., Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015; 27: 15-26.
20. Sorbye H, Glimelius B, Berglund A, et al., Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31-8.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
22. Van Loo P, Nordgard SH, Lingjaerde OC, et al., Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 2010; 107: 16910-15.
23. Loes IM, Immervoll H, Angelsen JH, et al., Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. Tumour Biol 2014; 36: 1003-13.
24. Chrisanthar R, Knappskog S, Lokkevik E, et al., CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008; 3: e3062.
25. Kaplan EL, Meier P., Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
26. Mantel N., Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
27. Cox DR., Regression models and life-tables. J R Stat Soc B 1972; 34: 187.
28. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
29. Rajagopalan H, Bardelli A, Lengauer C, et al., Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
30. Vakiani E, Janakiraman M, Shen R, et al., Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956-62.
31. Vermaat JS, Nijman IJ, Koudijs MJ, et al., Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res 2012; 18: 688-99.
32. Karagkounis G, Torbenson MS, Daniel HD, et al., Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013; 119: 4137-44.
33. Samowitz WS, Curtin K, Schaffer D, et al., Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
34. Iida S, Kato S, Ishiguro M, et al., PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett 2012; 3: 565-70.
35. Liao X, Morikawa T, Lochhead P, et al., Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18:2257-68.
36. Pietrantonio F, Biondani P, Perrone F, et al., TP53 mutations in advanced colorectal cancer: the dark side of the moon. Oncology 2014; 86: 289-94.
37. Russo A, Bazan V, Iacopetta B, et al., The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23: 7518-28.
38. Geisler S, Lonning PE, Aas T, et al., Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-12.
39. Sorbye H, Mauer M, Gruenberger T, et al., Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 2012; 255: 534-9.
40. Hanrahan EO, Hennessy BT, Valero V., Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacol 2005; 6: 1477-91.
41. Shi JH, Line PD., Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol 2014; 20: 16167-77.
42. Burrell RA, McGranahan N, Bartek J, et al., The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-45.
43. Bedard PL, Hansen AR, Ratain MJ, et al., Tumour heterogeneity in the clinic. Nature 2013; 501: 355-64.
44. Hiley C, de Bruin EC, McGranahan N, et al., Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 2014; 15: 453.
45. Yates LR, Gerstung M, Knappskog S, et al., Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 2015; 21: 751-9.
46. Normanno N, Rachiglio AM, Lambiase M, et al.,; on the behalf of the C-Gi. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 2015;26:1710-4.
47. Ciardiello F, Normanno N, Maiello E, et al., Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 2014; 25: 1756-61.
48. Maley CC, Galipeau PC, Finley JC, et al., Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38: 468-73.
49. Almendro V, Kim HJ, Cheng YK, et al., Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014; 74: 1338-48.
50. Mroz EA, Tward AD, Pickering CR, et al., High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 2013; 119: 3034-42.